, Columnist
No Quick Wins for GSK
Walmsley may struggle to maintain the drugmaker's premium valuation.
This article is for subscribers only.
Incoming CEOs like quick wins. But Emma Walmsley may find them elusive when she takes over at GlaxoSmithKline Plc in March.
Glaxo’s lead drug, Advair, will face competition from generics in the U.S. at some point next year. The pace at which its sales might decline is uncertain. Given it accounts for a quarter of pharmaceutical revenue, the threat is clear.